The non-compliance notice from Nasdaq is a significant regulatory issue for Trinity Biotech. Failure to meet the minimum bid price requirement could lead to delisting, which would negatively impact the company's stock price. The company has a period until March 6, 2024, to regain compliance, which adds a level of uncertainty and potential downward pressure on the stock in the short term.